SpecializedRx
3787 95th Ave NE, Ste 100
Circle Pines, MN. 55014 USA
888.512.1209
www.specializedrx.com

SUGGESTED PROCEDURE

Item	Diphenylcyclopropenone 0.01% Salicylic Acid 15% Ointment	Formula Date	14 MAY 2026
API(s)	Diphenylcyclopropenone, Salicylic Acid, USP	Procedure No.	P2786
Base	HelixGel™	Revision	R01
Volume/Quantity	100 g	Compound Type	Anhydrous Topical Ointment

Rx	Weight (g)	Percent	Comment
Diphenylcyclopropenone	0.01 g	0.01%	
Salicylic Acid, USP	15 g	15%	
Propanediol, NF	3 g	3%	
HelixGel™	87 g	87%	qs
Total	81.99 g	81.99%	

To account for processing error considerations during preparation, it is suggested to measure an additional **10%** of the required quantities of ingredients.

Suggested Method of Preparation

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh and/or measure each ingredient. Consider batch size and density conversions if required.
3. Triturate Salicylic Acid to a fine powder.
4. Geometrically incorporate HelixGel™ base to actives and mix well. If using an Unguator®, disposable blades are recommended to avoid excess heat and/or friction.
5. If final preparation is gritty, run through an ointment mill until smooth. No visible particulate should be present.
6. Final product should be a smooth, off-white to yellowish ointment.
7. Transfer the final preparation into an appropriate dispensing container.
8. Suggested Quality assessments
    a. Appearance and feel
    b. Quantity
    c. Label: auxiliary labels, storage, BUD, compounded medication, for external use only

Packaging: Tight, light-resistant container
Estimated Beyond Use Date: 180 days per USP 795*
Labeling: Keep out of reach of children. Use only as directed. Protect from moisture and light.
Stability: Anhydrous formulation.
Note: Potency Range Recommendation: ≥90% and ≤110% of the theoretically calculated active(s).
Note: All products, except for API(s) are sourced from SpecializedRx only. Any deviation from ingredients used will invalidate the formula.

***Beyond-Use Date should be based on the current USP General Chapter <795>.** Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist. Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

WARNING! Precautions should be taken when handling APIs as they can be absorbed through the skin, mucus membranes and lungs if inhaled. Always wear protective lab apparel, gloves, eye protection, respirator / work under a safety cabinet.